论文部分内容阅读
Osteosarcoma is a common malignant bone cancer in children and adolescents.In modern treatments,different chemotherapeutics drugs are administered combined either intravenously or orally both before and after surgery [1].Doxorubicin·hydrochloride (DOX·HCl),a broad-spectrum anti-tumor drug,has shown to be effective in osteosarcoma treatment.Additionally,gene therapy has been an emerging targeted therapeutic strategy for osteosarcoma treatment.For instance,polo-like kinase 1 (PLK1) gene has been chosen as a promising therapeutic target for osteosarcoma therapy,due to its involvement in carcinogenesis.Nevertheless,reports on the co-delivery of anti-tumor drugs and genes for combination cancer treatment through a localized and sustained strategy,such as by using biodegradable and injectable hydrogels,are still limited to-date [2,3].